Valbiotis (XPAR:ALVAL) Stock Based Compensation: €0.30 Mil (TTM As of Dec. 2025)


XPAR:ALVAL Valbiotis SA XPAR:ALVAL
55 GF Score
Price €0.81
GF Value €1.48
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Valbiotis Stock Based Compensation?

Valbiotis XPAR:ALVAL -1.83% 55 Stock Based Compensation is €0.30 Mil as of Dec. 2025. GuruFocus rates XPAR:ALVAL with a GF Score™ of 55/100 and a GF Value™ of €1.48 (Possible Value Trap). The stock has 6 warning signs investors should review.

Valbiotis's Stock Based Compensation for the six months ended in Dec. 2025 was €0.01 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was €0.30 Mil.

Valbiotis Stock Based Compensation Related Terms

Valbiotis Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Valbiotis's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valbiotis Stock Based Compensation Chart

Valbiotis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.45 2.34 0.60 0.63 0.30

Valbiotis Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.36 0.60 0.04 0.29 0.01
XPAR:ALVAL
55GF Score
Valbiotis SA XPAR:ALVAL
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Valbiotis Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.30 Mil.

What does a Stock Based Compensation of €0.30 Mil mean?
Valbiotis (XPAR:ALVAL) has a Stock Based Compensation of €0.30 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Valbiotis and its competitors.
Is Valbiotis' Stock Based Compensation too high?
Valbiotis' current Stock Based Compensation is €0.30 Mil. Overall, Valbiotis has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valbiotis' Stock Based Compensation compare to KHC and GIS?
Valbiotis' Stock Based Compensation of €0.30 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Consumer Packaged Goods company?
A good Stock Based Compensation depends on the Consumer Packaged Goods industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Valbiotis and its competitors. Valbiotis's current Stock Based Compensation is €0.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valbiotis stock overvalued right now?
Based on GuruFocus' analysis, Valbiotis (XPAR:ALVAL) is currently considered Possible Value Trap. The stock's GF Value™ is €1.48, compared to a current price of €0.81 — trading 45.6% below its estimated fair value. The current Stock Based Compensation is €0.30 Mil. Valbiotis' overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Valbiotis (XPAR:ALVAL), the current Stock Based Compensation is €0.30 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Valbiotis (XPAR:ALVAL) Overvalued in 2026?

Based on GuruFocus' analysis, Valbiotis stock appears to be undervalued. The current stock price of €0.81 is trading 45.6% below its estimated GF Value™ of €1.48. GuruFocus considers Valbiotis to be Possible Value Trap.

Key valuation signals for XPAR:ALVAL:

  • Stock Based Compensation: €0.30 Mil
  • GF Value™: €1.48 vs. price of €0.81 (45.6% below fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the XPAR:ALVAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Valbiotis Business Description

Other Exchanges 8JD:Germany
Address 12F rue Paul VATINE, Perigny, La Rochelle, FRA, 17180
Valbiotis SA is a research & development company. It is engaged in scientific innovation for preventing and combating metabolic diseases. Valbiotis has adopted an approach, aiming to revolutionize healthcare by developing a new class of Nutrition Health products designed to reduce the risk of metabolic diseases, based on a multi-target approach by the use of plant-based ingredients.
55GF Score

Get the complete analysis for XPAR:ALVAL

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.81
Price
€1.48
GF Value